Please login to the form below

Not currently logged in

licence deal

This page shows the latest licence deal news and features for those working in and with pharma, biotech and healthcare.

Otsuka licenses Lundbeck’s Alzheimer's drug in $825m deal

Otsuka licenses Lundbeck’s Alzheimer's drug in $825m deal

Otsuka licenses Lundbeck’ s Alzheimer's drug in $825m deal. Lu AE58054 is in phase III development as add-on to donepezil. ... Japanese pharma company Otsuka has licensed an Alzheimer's disease drug candidate from Lundbeck in a deal that expands an

Latest news

  • Pharma deals during August 2012 Pharma deals during August 2012

    Second in the table was the classic global licence and development deal between Genmab and Janssen Biotech [part of J&J] for daratumumab [HuMax – CD-38], which was announced at the ... This deal follows on from that reported in December 2009 when Aspen

  • J&J signs $1.1bn deal with Genmab for cancer antibody

    J&J signs $1.1bn deal with Genmab for cancer antibody. Licenses daratumumab in development for multiple myeloma. ... J&J has taken an almost 11 per cent equity stake in Genmab for around $80m and paid $55m upfront for the licence, with the balance of the

  • AZ moves to strengthen diabetes, cancer pipelines

    Tokyo-based Prosidion has already advanced the lead compound in the licence deal - called PSN821 - into phase II testing, while AstraZeneca has also take an option for a follow-up (PSN842) ... AstraZeneca has paid Prosidion an undisclosed option fee

  • Eastern Europe targeted

    The largest licence deal in May, financially, was that reported between Glenmark and Sanofi. ... COPD). As Almirall will be developing its own brand, this deal is more like a licence and as such commanded an undisclosed upfront fee.

  • FDA places hold on AIDS drug

    The US Food and Drug Administration (FDA) has placed a clinical hold on an experimental HIV/AIDS drug being developed by GlaxoSmithKline (GSK) under a licence from Idenix Pharmaceuticals. ... Idenix has so far received $60.5m in licence fees under the

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... The deal also includes a licence to

  • Deal Watch October 2016 Deal Watch October 2016

    Astellas has structured its deal almost like a licence with one third of the consideration ($462m) upfront and the remainder in “ further contingent milestones” (milestones and possibly royalties) as the product ... The licence deal obtained by

  • Deal Watch May 2016 Deal Watch May 2016

    Building on its 2014 deal with MacroGenics, J&J entered into a licence and collaboration agreement for MGD015 for B-cell malignancies with an upfront fee of $75m and $665m in ... Another deal which has taken a hybrid licence / acquisition format is that

  • Deal Watch January 2016 Deal Watch January 2016

    The original deal was a worldwide exclusive licence for the commercialisation of Afrezza in diabetes, with expected peak sales in the range of $0.6bn to $1.0bn (the first nine ... Licensor/Acquired Acquiror/Partner. Deal Type. Comments. Hline $m. Baxalta/

  • Pharma deals in July 2015 Pharma deals in July 2015

    Biogen also broke the $1bn headline in a licence and collaboration deal with AGTC for gene based therapies to treat ophthalmic diseases. ... A strange coincidence! Licensor/Licensee Acquired / Acquirer. Deal type. Product/Technology. Headline $m.

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...